Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice

Sanjaya Satapathy, Mahendar Ochani, Meghan Dancho, Laqueta K. Hudson, Mauricio Rosas-Ballina, Sergio I. Valdes-Ferrer, Peder S. Olofsson, Yael Tobi Harris, Jesse Roth, Sangeeta Chavan, Kevin J. Tracey, Valentin A. Pavlov

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Obesity, a serious and growing health threat, is associated with low-grade inflammation that plays a role in mediating its adverse consequences. Previously, we have discovered a role for neural cholinergic signaling in controlling inflammation, and demonstrated that the cholinergic agent galantamine suppresses excessive proinflammatory cytokine release. The main objective of this study was to examine the efficacy of galantamine, a clinically-approved drug, in alleviating obesity-related inflammation and associated complications. After 8 wks on a high-fat diet, C57BL/6J mice were treated with either galantamine (4 mg/kg, intraperitoneally [i.p.]) or saline for 4 wks in parallel with mice on a low-fat diet and treated with saline. Galantamine treatment of obese mice significantly reduced body weight, food intake, abdominal adiposity, plasma cytokine and adipokine levels, and significantly improved blood glucose, insulin resistance and hepatic steatosis. In addition, galantamine alleviated impaired insulin sensitivity and glucose intolerance significantly. These results indicate a previously unrecognized potential of galantamine in alleviating obesity, inflammation and other obesity-related complications in mice. These findings are of interest for studying the efficacy of this clinically-approved drug in the context of human obesity and metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)599-606
Number of pages8
JournalMolecular Medicine
Volume17
Issue number7-8
DOIs
StatePublished - Jul 1 2011

Fingerprint

Galantamine
High Fat Diet
Obesity
Inflammation
Cholinergic Agents
Insulin Resistance
Cytokines
Obese Mice
Fat-Restricted Diet
Adipokines
Glucose Intolerance
Adiposity
Inbred C57BL Mouse
Pharmaceutical Preparations
Blood Glucose
Eating
Body Weight
Liver
Health

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Satapathy, S., Ochani, M., Dancho, M., Hudson, L. K., Rosas-Ballina, M., Valdes-Ferrer, S. I., ... Pavlov, V. A. (2011). Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Molecular Medicine, 17(7-8), 599-606. https://doi.org/10.2119/molmed.2011.00083

Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. / Satapathy, Sanjaya; Ochani, Mahendar; Dancho, Meghan; Hudson, Laqueta K.; Rosas-Ballina, Mauricio; Valdes-Ferrer, Sergio I.; Olofsson, Peder S.; Harris, Yael Tobi; Roth, Jesse; Chavan, Sangeeta; Tracey, Kevin J.; Pavlov, Valentin A.

In: Molecular Medicine, Vol. 17, No. 7-8, 01.07.2011, p. 599-606.

Research output: Contribution to journalArticle

Satapathy, S, Ochani, M, Dancho, M, Hudson, LK, Rosas-Ballina, M, Valdes-Ferrer, SI, Olofsson, PS, Harris, YT, Roth, J, Chavan, S, Tracey, KJ & Pavlov, VA 2011, 'Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice', Molecular Medicine, vol. 17, no. 7-8, pp. 599-606. https://doi.org/10.2119/molmed.2011.00083
Satapathy, Sanjaya ; Ochani, Mahendar ; Dancho, Meghan ; Hudson, Laqueta K. ; Rosas-Ballina, Mauricio ; Valdes-Ferrer, Sergio I. ; Olofsson, Peder S. ; Harris, Yael Tobi ; Roth, Jesse ; Chavan, Sangeeta ; Tracey, Kevin J. ; Pavlov, Valentin A. / Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. In: Molecular Medicine. 2011 ; Vol. 17, No. 7-8. pp. 599-606.
@article{c1f217558bac4c68a22b47c327931d62,
title = "Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice",
abstract = "Obesity, a serious and growing health threat, is associated with low-grade inflammation that plays a role in mediating its adverse consequences. Previously, we have discovered a role for neural cholinergic signaling in controlling inflammation, and demonstrated that the cholinergic agent galantamine suppresses excessive proinflammatory cytokine release. The main objective of this study was to examine the efficacy of galantamine, a clinically-approved drug, in alleviating obesity-related inflammation and associated complications. After 8 wks on a high-fat diet, C57BL/6J mice were treated with either galantamine (4 mg/kg, intraperitoneally [i.p.]) or saline for 4 wks in parallel with mice on a low-fat diet and treated with saline. Galantamine treatment of obese mice significantly reduced body weight, food intake, abdominal adiposity, plasma cytokine and adipokine levels, and significantly improved blood glucose, insulin resistance and hepatic steatosis. In addition, galantamine alleviated impaired insulin sensitivity and glucose intolerance significantly. These results indicate a previously unrecognized potential of galantamine in alleviating obesity, inflammation and other obesity-related complications in mice. These findings are of interest for studying the efficacy of this clinically-approved drug in the context of human obesity and metabolic syndrome.",
author = "Sanjaya Satapathy and Mahendar Ochani and Meghan Dancho and Hudson, {Laqueta K.} and Mauricio Rosas-Ballina and Valdes-Ferrer, {Sergio I.} and Olofsson, {Peder S.} and Harris, {Yael Tobi} and Jesse Roth and Sangeeta Chavan and Tracey, {Kevin J.} and Pavlov, {Valentin A.}",
year = "2011",
month = "7",
day = "1",
doi = "10.2119/molmed.2011.00083",
language = "English (US)",
volume = "17",
pages = "599--606",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",
number = "7-8",

}

TY - JOUR

T1 - Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice

AU - Satapathy, Sanjaya

AU - Ochani, Mahendar

AU - Dancho, Meghan

AU - Hudson, Laqueta K.

AU - Rosas-Ballina, Mauricio

AU - Valdes-Ferrer, Sergio I.

AU - Olofsson, Peder S.

AU - Harris, Yael Tobi

AU - Roth, Jesse

AU - Chavan, Sangeeta

AU - Tracey, Kevin J.

AU - Pavlov, Valentin A.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Obesity, a serious and growing health threat, is associated with low-grade inflammation that plays a role in mediating its adverse consequences. Previously, we have discovered a role for neural cholinergic signaling in controlling inflammation, and demonstrated that the cholinergic agent galantamine suppresses excessive proinflammatory cytokine release. The main objective of this study was to examine the efficacy of galantamine, a clinically-approved drug, in alleviating obesity-related inflammation and associated complications. After 8 wks on a high-fat diet, C57BL/6J mice were treated with either galantamine (4 mg/kg, intraperitoneally [i.p.]) or saline for 4 wks in parallel with mice on a low-fat diet and treated with saline. Galantamine treatment of obese mice significantly reduced body weight, food intake, abdominal adiposity, plasma cytokine and adipokine levels, and significantly improved blood glucose, insulin resistance and hepatic steatosis. In addition, galantamine alleviated impaired insulin sensitivity and glucose intolerance significantly. These results indicate a previously unrecognized potential of galantamine in alleviating obesity, inflammation and other obesity-related complications in mice. These findings are of interest for studying the efficacy of this clinically-approved drug in the context of human obesity and metabolic syndrome.

AB - Obesity, a serious and growing health threat, is associated with low-grade inflammation that plays a role in mediating its adverse consequences. Previously, we have discovered a role for neural cholinergic signaling in controlling inflammation, and demonstrated that the cholinergic agent galantamine suppresses excessive proinflammatory cytokine release. The main objective of this study was to examine the efficacy of galantamine, a clinically-approved drug, in alleviating obesity-related inflammation and associated complications. After 8 wks on a high-fat diet, C57BL/6J mice were treated with either galantamine (4 mg/kg, intraperitoneally [i.p.]) or saline for 4 wks in parallel with mice on a low-fat diet and treated with saline. Galantamine treatment of obese mice significantly reduced body weight, food intake, abdominal adiposity, plasma cytokine and adipokine levels, and significantly improved blood glucose, insulin resistance and hepatic steatosis. In addition, galantamine alleviated impaired insulin sensitivity and glucose intolerance significantly. These results indicate a previously unrecognized potential of galantamine in alleviating obesity, inflammation and other obesity-related complications in mice. These findings are of interest for studying the efficacy of this clinically-approved drug in the context of human obesity and metabolic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=79960740892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960740892&partnerID=8YFLogxK

U2 - 10.2119/molmed.2011.00083

DO - 10.2119/molmed.2011.00083

M3 - Article

VL - 17

SP - 599

EP - 606

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

IS - 7-8

ER -